Zacks: Brokerages Anticipate AngioDynamics, Inc. (ANGO) to Announce $0.26 Earnings Per Share

Wall Street brokerages expect AngioDynamics, Inc. (NASDAQ:ANGO) to announce earnings of $0.26 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AngioDynamics’ earnings. The highest EPS estimate is $0.26 and the lowest is $0.25. AngioDynamics posted earnings per share of $0.20 during the same quarter last year, which would suggest a positive year-over-year growth rate of 30%. The firm is expected to issue its next earnings report on Wednesday, July 10th.

On average, analysts expect that AngioDynamics will report full year earnings of $0.84 per share for the current fiscal year, with EPS estimates ranging from $0.83 to $0.84. For the next financial year, analysts anticipate that the firm will report earnings of $0.97 per share, with EPS estimates ranging from $0.95 to $0.98. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow AngioDynamics.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.03). The firm had revenue of $86.34 million for the quarter, compared to analysts’ expectations of $88.30 million. AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. AngioDynamics’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 earnings per share.

A number of equities analysts recently weighed in on ANGO shares. Canaccord Genuity boosted their price target on shares of AngioDynamics from $20.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, January 7th. BidaskClub downgraded shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 6th. Zacks Investment Research downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. ValuEngine cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, April 19th. Finally, TheStreet cut AngioDynamics from a “b” rating to a “c+” rating in a research note on Thursday, April 18th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $23.50.

Shares of NASDAQ:ANGO traded up $0.21 during midday trading on Friday, reaching $20.71. The company had a trading volume of 5,126 shares, compared to its average volume of 238,269. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68. The company has a market capitalization of $762.93 million, a P/E ratio of 27.95 and a beta of 0.75. AngioDynamics has a 52-week low of $18.11 and a 52-week high of $25.48.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Thrivent Financial for Lutherans boosted its position in AngioDynamics by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 26,360 shares of the medical instruments supplier’s stock worth $531,000 after purchasing an additional 579 shares in the last quarter. Advisor Group Inc. increased its stake in AngioDynamics by 21.4% during the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 601 shares during the last quarter. Texas Permanent School Fund increased its stake in AngioDynamics by 4.1% during the fourth quarter. Texas Permanent School Fund now owns 24,292 shares of the medical instruments supplier’s stock worth $489,000 after acquiring an additional 964 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in AngioDynamics by 28.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 1,181 shares during the last quarter. Finally, United Services Automobile Association increased its stake in AngioDynamics by 9.8% during the fourth quarter. United Services Automobile Association now owns 17,816 shares of the medical instruments supplier’s stock worth $359,000 after acquiring an additional 1,595 shares during the last quarter. Hedge funds and other institutional investors own 99.71% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: What is a resistance level?

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.